Improving therapeutic potential in breast cancer via histone deacetylase inhibitor loaded nanofibrils

IF 3.5 4区医学 Q2 CHEMISTRY, MEDICINAL

Drug Development Research Pub Date : 2024-03-15 DOI:10.1002/ddr.22172

Praveetha Senthilkumar, Bhaskar Gogoi, Swati Smita Dhan, Ramesh Subramani, Charumathi Pushparaj, Ayyavu Mahesh

{"title":"Improving therapeutic potential in breast cancer via histone deacetylase inhibitor loaded nanofibrils","authors":"Praveetha Senthilkumar, Bhaskar Gogoi, Swati Smita Dhan, Ramesh Subramani, Charumathi Pushparaj, Ayyavu Mahesh","doi":"10.1002/ddr.22172","DOIUrl":null,"url":null,"abstract":"<p>Epigenetic modifications play a significant role in cancer progression, making them potential targets for therapy. Histone deacetylase inhibitors have shown promise in inhibiting cancer cell growth, including in breast cancer (BC). In this research, we examined the potential of using suberoyl anilide hydroxamic acid (SAHA)-loaded β-lg nanofibrils as a drug delivery system for triple-negative BC cell lines. We assessed their impact on cell cycle progression, apoptosis, levels of reactive oxygen species, and mitochondrial membrane potential in cancer cells. The combination of SAHA and β-lg nanofibrils demonstrated enhanced efficacy in inhibiting cell growth, inducing cell cycle arrest, and promoting apoptosis (43.78%) compared to SAHA alone (40.09%). Moreover, it effectively targeted cancer cells without promoting drug resistance while using a low concentration of the nanofibrils. These findings underscore the promising potential of nanofibril-based drug delivery systems for BC treatment.</p>","PeriodicalId":11291,"journal":{"name":"Drug Development Research","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Development Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ddr.22172","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Epigenetic modifications play a significant role in cancer progression, making them potential targets for therapy. Histone deacetylase inhibitors have shown promise in inhibiting cancer cell growth, including in breast cancer (BC). In this research, we examined the potential of using suberoyl anilide hydroxamic acid (SAHA)-loaded β-lg nanofibrils as a drug delivery system for triple-negative BC cell lines. We assessed their impact on cell cycle progression, apoptosis, levels of reactive oxygen species, and mitochondrial membrane potential in cancer cells. The combination of SAHA and β-lg nanofibrils demonstrated enhanced efficacy in inhibiting cell growth, inducing cell cycle arrest, and promoting apoptosis (43.78%) compared to SAHA alone (40.09%). Moreover, it effectively targeted cancer cells without promoting drug resistance while using a low concentration of the nanofibrils. These findings underscore the promising potential of nanofibril-based drug delivery systems for BC treatment.

查看原文本刊更多论文

通过负载组蛋白去乙酰化酶抑制剂的纳米纤维提高乳腺癌的治疗潜力。

表观遗传修饰在癌症进展中起着重要作用，因此成为潜在的治疗目标。组蛋白去乙酰化酶抑制剂有望抑制癌细胞生长，包括乳腺癌（BC）。在这项研究中，我们考察了使用亚伯酰苯胺羟肟酸（SAHA）负载的β-lg纳米纤维作为药物输送系统治疗三阴性BC细胞系的潜力。我们评估了它们对癌细胞的细胞周期进展、细胞凋亡、活性氧水平和线粒体膜电位的影响。与单独使用SAHA（40.09%）相比，SAHA和β-lg纳米纤维的组合在抑制细胞生长、诱导细胞周期停滞和促进细胞凋亡方面的效力更高（43.78%）。此外，在使用低浓度纳米纤维的同时，它还能有效地靶向癌细胞，而不会产生耐药性。这些发现凸显了基于纳米纤维的药物输送系统在治疗癌细胞转移方面的巨大潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Development Research 医学-药学

CiteScore

6.40

自引率

2.60%

发文量

104

审稿时长

6-12 weeks

期刊介绍： Drug Development Research focuses on research topics related to the discovery and development of new therapeutic entities. The journal publishes original research articles on medicinal chemistry, pharmacology, biotechnology and biopharmaceuticals, toxicology, and drug delivery, formulation, and pharmacokinetics. The journal welcomes manuscripts on new compounds and technologies in all areas focused on human therapeutics, as well as global management, health care policy, and regulatory issues involving the drug discovery and development process. In addition to full-length articles, Drug Development Research publishes Brief Reports on important and timely new research findings, as well as in-depth review articles. The journal also features periodic special thematic issues devoted to specific compound classes, new technologies, and broad aspects of drug discovery and development.